Akhila Reddy, Ali Haider, Joseph Arthur, David Hui, Shalini Dalal, Rony Dev, Kimberson Tanco, Jaya Amaram-Davila, Farley Hernandez, Paul Chavez, Aline Rozman De Moraes, Jimin Wu, Kristy Nguyen, Ishwaria Subbiah, Daniel Epner, Zeena Shelal, Marvin Omar Delgado Guay, Tarun Mallipeddi, Eduardo Bruera
CONTEXT: Levorphanol is a potent opioid agonist and NMDA receptor blocker with minimal drug interactions, and there are few reports of its use in cancer patients. OBJECTIVES: We aimed to determine the frequency of successful opioid rotation (OR) to levorphanol and the median opioid rotation ratio (ORR) from Morphine Equivalent Daily Dose (MEDD). METHODS: This is a prospective, single-group, interventional study. Cancer outpatients requiring an OR and receiving a MEDD of 60-300 mg were rotated to levorphanol using a ratio of 10:1 and assessed daily for 10-day...
June 2023: Journal of Pain and Symptom Management